The Online Investor

Slideshow Mergers & Acquisitions

By The Online Investor Staff, updated Wed., Feb. 26, 4:35 PM

Slide #30. Tocagen Inc. Forte Biosciences, Inc.

Acquirer: Tocagen Inc. (NASDAQ:TOCA)
Acquiree: Forte Biosciences, Inc.
Details: Tocagen Inc. (Nasdaq: TOCA), and Forte Biosciences, Inc., a privately held clinical-stage biopharmaceutical company developing a live biotherapeutic for the treatment of inflammatory skin diseases, announced today that they have entered into a definitive agreement under which Tocagen will merge with Forte in an all-stock transaction. The merged company will focus on advancing Forte's clinical program in inflammatory skin diseases, including atopic dermatitis. Upon stockholder approval, the combined company is expected to operate under the name Forte Biosciences and trade on the Nasdaq Capital Market under the ticker symbol FBRX.

Tocagen is a clinical-stage, cancer-selective gene therapy company focused on developing product candidates designed to activate a patient's immune system against their own cancer. Co. is developing its primary product candidate, Toca 511 (vocimagene amiretrorepvec) and Toca FC (extended-release flucytosine), for the treatment of recurrent high grade glioma, a brain cancer with limited treatment options, low survival rates and, therefore, an unmet medical need. In addition, Co. is developing other retroviral replicating vectors to deliver genes to cancer cells against validated immunotherapy targets.

TOCA SEC Filing Email Alerts Service

Open the TOCA Page at The Online Investor »

Company Name: 
Tocagen Inc
Drugs & Pharmaceuticals
Number of ETFs Holding TOCA: 
Total Market Value Held by ETFs: 
Total Market Capitalization: 
% of Market Cap. Held by ETFs: 

Open the TOCA Page at The Online Investor (in a new window) »

Quotes delayed 20 minutes

Hold (2.00 out of 4)
0th percentile
(ranked lower than approx. 100% of all stocks covered)
Based on Zacks ABR data;
powered by Xignite

Mergers & Acquisitions Page |

Copyright © 1998 - 2020, All Rights Reserved
Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes; data powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.